


## WHAT IS CLAIMED IS:

1. A compound of Formula (I)

One embodiment provides a compound of Formula (I):



or a stereoisomer or a pharmaceutically acceptable salt thereof,

wherein:

$R^1$  is:  $C_{1-6}$ alkyl; cyano- $C_{1-6}$ alkyl;  $C_{1-6}$ alkoxy-(CO)-;  $-(CHR^a)_m-NR^bR^c$ ; or  $-(CHR^a)_n$ -het<sup>1</sup>;

$R^2$  is:  $C_{1-6}$ alkyl; hydroxy- $C_{1-6}$ alkyl; halo- $C_{1-6}$ alkyl;  $C_{1-6}$ alkoxy- $C_{1-6}$ alkyl;  $C_{3-6}$ cycloalkyl;  $-(CHR^a)_p-NR^bR^c$ ; het<sup>2</sup>;  $-(CHR^a)_q$ -het<sup>3</sup>; or phenyl which may be unsubstituted or substituted once or twice with  $R^d$ ;

$R^3$  is: hydrogen; or  $C_{1-6}$ alkyl;

$R^4$  is: hydrogen; or  $C_{1-6}$ alkyl;

$R^5$  is: hydrogen; or  $C_{1-6}$ alkyl;

$R^6$  is: hydrogen;  $C_{1-6}$ alkyl; or  $R^2$  and  $R^6$  together with the atoms to which they are attached may form a six membered ring;

$m$  is from 2 to 3;

$n$  is from 0 to 2;

$p$  is from 0 to 2;

each  $R^a$  is independently: hydrogen; or  $C_{1-6}$ alkyl;

each  $R^b$  is independently: hydrogen; or  $C_{1-6}$ alkyl;

each  $R^c$  is independently: hydrogen; or  $C_{1-6}$ alkyl;

het<sup>1</sup> is: tetrahydrofuranyl; azetidiny; or pyrrolidinyl, each of which may be unsubstituted or substituted once or twice with R<sup>e</sup>;

het<sup>2</sup> is: pyridinyl; pyrimidinyl; pyrazolyl; imidazolyl; or isoquinolinyl which may be partially saturated; each of which may be unsubstituted or substituted once or twice with R<sup>f</sup>;

het<sup>3</sup> is: azetidiny; pyrrolidinyl; oxetanyl; or piperidinyl; each of which may be unsubstituted or substituted once with R<sup>g</sup>;

each R<sup>d</sup> is independently: C<sub>1-6</sub>alkyl; hydroxy; C<sub>1-6</sub>alkoxy-C<sub>1-6</sub>alkyl; -(CHR<sup>a</sup>)<sub>q</sub>-NR<sup>b</sup>R<sup>c</sup>; or phenyl;

each R<sup>e</sup> is independently: C<sub>1-6</sub>alkyl; or oxo;

each R<sup>f</sup> is independently: C<sub>1-6</sub>alkyl; hydroxy-C<sub>1-6</sub>alkyl; oxo; -(CHR<sup>a</sup>)<sub>r</sub>-NR<sup>b</sup>R<sup>c</sup>; -(CHR<sup>a</sup>)<sub>s</sub>-het<sup>4</sup>;

each R<sup>g</sup> is independently: C<sub>1-6</sub>alkyl; or acetyl;

q is from 1 to 2;

r is from 2 to 3;

s is from 2 to 3; and

het<sup>4</sup> is: azetidin-1-yl; 1-methyl-azetidin-3-yl; quinuclidinyl; 1-methyl-pyrrolidin-2-yl; or 4-methylpiperazin-1-yl.

2. The compound of claim 1 or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen.

3. The compound of claim 1 or 2, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is cyanomethyl or methyl.

4. The compound of any of claims 1-3, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is cyanomethyl.

5. The compound of any of claims 1-3, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is methyl.

6. The compound of any of claims 1-5, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is: C<sub>1-6</sub>alkyl; hydroxy-C<sub>1-6</sub>alkyl; halo-C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkoxy-C<sub>1-6</sub>alkyl; C<sub>3-6</sub>cycloalkyl; -(CHR<sup>a</sup>)<sub>p</sub>-NR<sup>b</sup>R<sup>c</sup>; het<sup>2</sup>; -(CHR<sup>a</sup>)<sub>q</sub>-het<sup>3</sup>; or phenyl which may be unsubstituted or substituted once with R<sup>d</sup>.


7. The compound of any of claims 1-6, wherein R<sup>2</sup> is C<sub>1-6</sub>alkyl, hydroxy-C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkoxy-C<sub>1-6</sub>alkyl or halo-C<sub>1-6</sub>alkyl.

8. The compound of any of claims 1-7, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is hydroxy-C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy-C<sub>1-6</sub>alkyl.

9. The compound of any of claims 1-5, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein  $R^2$  is 2-hydroxyethyl, difluoromethoxy, 3-hydroxyphenyl, -methoxyphenyl, 2-hydroxypropyl, pyridine-4-yl, methyl, azetidin-yl, 2-hydroxy-1-methyl-ethyl, methylamino, dimethylamino, 1-methyl-pyrazol-4-yl, phenyl, pyrazol-4-yl, 1-methyl-2-oxo-4-pyridyl, or 2-hydroxy-1-methyl-propyl.


10. The compound of any of claims 1-5, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein  $R^2$  is 2-hydroxyethyl, 2-hydroxypropyl, 2-hydroxy-1-methyl-ethyl, or 2-hydroxy-1-methyl-propyl.

11. The compound of claim 1, wherein the compound is of formula (II)




or a stereoisomer or a pharmaceutically acceptable salt thereof.


12. The compound of claim 1, wherein the compound is of formula (III)





or a stereoisomer or a pharmaceutically acceptable salt thereof.


13. The compound of claim 1, selected from:















and



; or a stereoisomer or a pharmaceutically acceptable salt thereof.

14. A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of claims 1-13, or a stereoisomer or pharmaceutically acceptable salt thereof.

15. The method of claim 14, wherein the disease or condition is cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, multiple sclerosis, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, asthma, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation (e.g., transplant rejection), immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, CNS disorders or a myeloproliferative disorder.
16. A pharmaceutical composition comprising a compound of any of claims 1-13, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition comprises microparticles of the compound suitable for inhaled delivery.
17. The pharmaceutical composition of claim 16, wherein the microparticles are prepared by spray-drying, freeze-drying or micronisation.
18. A kit comprising:
- (a) a first pharmaceutical composition comprising a compound of any of claims 1-13 or a stereoisomer or pharmaceutically acceptable salt thereof; and
  - (b) instructions for use.
19. The kit of claim 14, further comprising a second pharmaceutical composition comprising an agent for treatment of an inflammatory disorder, or a chemotherapeutic agent.
20. Use of a compound of any of claims 1-13 or a stereoisomer or pharmaceutically acceptable salt thereof for treatment of an inflammatory disease.
21. Use of a compound of any of claims 1-13 or a stereoisomer or pharmaceutically acceptable salt thereof for preparation of a medicament for treatment of an inflammatory disease.
23. Use of a compound of any of claims 20-21 or a stereoisomer or pharmaceutically acceptable salt thereof wherein the inflammatory disease is asthma.
24. The invention as described herein.